EBV DNA in plasma had better sensitivity (A) and specificity (B) than PBMCs in distinguishing between patients with active, systemic EBV+ disease and patients that did not have prior, current, or subsequent history of EBV+ disease. See Figure 2B-C in the article by Kanakry et al that begins on page 2007.

EBV DNA in plasma had better sensitivity (A) and specificity (B) than PBMCs in distinguishing between patients with active, systemic EBV+ disease and patients that did not have prior, current, or subsequent history of EBV+ disease. See Figure 2B-C in the article by Kanakry et al that begins on page 2007.

Close Modal

or Create an Account

Close Modal
Close Modal